Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Get Free Report) (TSE:AUP) has earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $17.75.
AUPH has been the topic of a number of recent research reports. TD Cowen increased their price target on shares of Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday. Wall Street Zen lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings raised shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday. Zacks Research lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Finally, Royal Bank Of Canada boosted their price objective on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Friday, August 7th.
Check Out Our Latest Research Report on AUPH
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of AUPH. Signaturefd LLC raised its holdings in Aurinia Pharmaceuticals by 360.0% in the 3rd quarter. Signaturefd LLC now owns 1,794 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,404 shares in the last quarter. Nykredit A S purchased a new stake in Aurinia Pharmaceuticals in the second quarter worth $35,000. Global Retirement Partners LLC purchased a new stake in Aurinia Pharmaceuticals in the second quarter worth $41,000. Quantbot Technologies LP bought a new position in Aurinia Pharmaceuticals in the second quarter worth $45,000. Finally, Frazier Financial Advisors LLC raised its holdings in Aurinia Pharmaceuticals by 411.9% in the first quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 2,793 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.
Aurinia Pharmaceuticals Price Performance
Shares of Aurinia Pharmaceuticals stock opened at $16.86 on Friday. The company has a current ratio of 5.42, a quick ratio of 4.97 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $2.24 billion, a PE ratio of 7.36 and a beta of 1.60. The business’s 50-day moving average price is $16.38 and its 200-day moving average price is $16.03. Aurinia Pharmaceuticals has a 12 month low of $11.57 and a 12 month high of $19.25.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The company had revenue of $58.57 million for the quarter, compared to analysts’ expectations of $80.45 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. Sell-side analysts forecast that Aurinia Pharmaceuticals will post 0.91 EPS for the current fiscal year.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.
Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.
Featured Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
- Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
- Can Planet Fitness Get Its Growth Back in Shape?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
